Drug Trial Radar · NCT03510325
Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)
Last checked: Nov 19, 2026Latest source record: Apr 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
762
Actual
Start
Feb 12, 2019
Primary completion
Sep 27, 2023
Study completion Sep 27, 2023
Sponsor
- Lead sponsor
- Shanghai Mental Health CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 27, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 16 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a sequential multiple-assignment randomized trial (RCT) of antipsychotic medication treatment in first-episode schizophrenia patients in the real-world settings.Through analysis of treatment efficacy rate and adverse reactions and pharmacoeconomic evaluation, this project intends to provide evidence for the selection of antipsychotics in FES patients as well as the efficacy and safety of using clozapine in the early phase of schizophrenia treatment by comparing with other SGAs.
Conditions
- Schizophrenia
Interventions
Phase 1: OlanzapineDrug
Initial dosage: 5-10 mg; recommended dosage: 5-20 mg/d; dosage form: po. duration: 8 weeks
Phase 1: RisperidoneDrug
Initial dosage: 1-2 mg; recommended dosage: 2-6 mg/d; dosage form: po. duration: 8 weeks
Phase 1: AmisulprideDrug
Initial dosage: 200-400 mg; recommended dosage: 400-1200 mg/d; dosage form: po. duration: 8 weeks
Phase 1: AripiprazoleDrug
Initial dosage: 5-10 mg; recommended dosage: 10-30 mg/d; dosage form: po. duration: 8 weeks
Phase 1: PerphenazineDrug
Initial dosage: 2-4 mg; recommended dosage: 6-36 mg/d; dosage form: po. duration: 8 weeks
Phase 2: OlanzapineDrug
Initial dosage: 5-10 mg; recommended dosage: 5-20 mg/d; dosage form: po. duration: 8 weeks
Phase 2: AmisulprideDrug
Initial dosage: 200-400 mg; recommended dosage: 400-1200 mg/d; dosage form: po. duration: 8 weeks
Phase 2: ClozapineDrug
Initial dosage: 25-50 mg; recommended dosage: 200-400 mg/d; dosage form: po. duration: 8 weeks
Phase 3A: Clozapine extended treatment or Combined clozapine-MECT therapyOther
Clozapine extended treatment: dosage: 200-600 mg/d; dosage form: po. Combined clozapine-MECT therapy: Dosage of clozapine: 200-600 mg/d; The modified electroconvulsive therapy (MECT) will be administered three times per week for the first 2 weeks, then twice a week for the next 2 weeks. The total treatment duration is about one month.
Phase 3B: Clozapine or another SGAsDrug
Clozapine: Initial dosage: 25-50 mg; recommended dosage: 200-600 mg/d; duration: 8 weeks Another Second generation antipsychotics (SGAs) (not previously used in phase 1 and 2): Olanzapine, risperidone, amisulpride, or aripiprazole The dosage of each drug is the same as that of phase 1 and phase 2.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment efficacy rateTime frame: baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months
- All-cause dropout rateTime frame: baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Beijing Anding Hospital of Capital Medical University
Beijing, Beijing Municipality, China
Renmin Hospital of Wuhan University
Wuhan, Hubei, China
Nanjing Brain Hospital Affiliated to Nanjing Medical University
Nanjing, Jiangsu, China
Dalian Seventh People's Hospital
Dalian, Liaoning, China
Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China
Hangzhou Seventh People's Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.